ArticleMolecular and cellular biochemistry2017

Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug.

Samaresh Sau et al.PubMed ↗Publisher ↗

No numbers read from the abstract.